Every S-1 that BioRestorative Therapies, Inc. (BRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow BRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRTX filings page.
BioRestorative Therapies, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibit-only update. The amendment adds a Form of Placement Agency Agreement, identified as Exhibit 10.51, and replaces the prior Filing Fee Table with a corrected version, filed as Exhibit 107.
The company states that the prospectus and the remaining portions of Part II of the original registration statement are unchanged and therefore omitted from this amendment. The filing is signed by President and Chief Executive Officer Lance Alstodt and other officers and directors, confirming authorization of this technical update to the pending registration.
BioRestorative Therapies is registering up to 9,708,738 Units, each with one share of common stock (or one pre-funded warrant) and one common stock warrant, for an assumed public offering price of $1.03 per Unit, implying approximately $10,000,000 in gross proceeds and about $9.0 million in estimated net proceeds.
Shares of common stock outstanding were 8,876,242 as of February 4, 2026, rising to up to 18,584,980 shares if the maximum number of Units is sold, excluding warrant and option exercises and other convertible securities. The common stock and pre-funded warrants are paired with five-year warrants and feature 4.99% or 9.99% beneficial ownership caps.
The company develops cell-based therapies for disc/spine disease (BRTX-100), metabolic disorders (ThermoStem) and operates a biocosmeceutical platform. It is a smaller reporting company with an accumulated deficit of $166,713,054 as of September 30, 2025, recurring losses, negative operating cash flows and disclosed substantial doubt about its ability to continue as a going concern.
BioRestorative Therapies, Inc. is registering up to 508,592 shares of common stock for resale by existing selling securityholders, with the shares issuable upon exercise of certain warrants. The warrants have an exercise price of $2.75 per share, and the company would receive up to $1,398,628 in gross proceeds only if they are fully exercised, which it currently plans to use for general corporate purposes and working capital, including its clinical trial and other initiatives. As of November 17, 2025, 8,876,242 shares of common stock were outstanding, a baseline figure for the company’s equity. BioRestorative develops cell-based therapies for spine disease (BRTX-100), metabolic disorders (ThermoStem) and operates a commercial biocosmeceutical platform. The shares will be sold from time to time by the selling securityholders, and investing in this stock is described as involving a high degree of risk, with the company’s audited financials including a going concern explanatory paragraph.